4.6 Article

Hepatitis C Virus Core Protein Augments Androgen Receptor-Mediated Signaling

期刊

JOURNAL OF VIROLOGY
卷 82, 期 22, 页码 11066-11072

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.01300-08

关键词

-

类别

资金

  1. National Institutes of Health [AI045144, AI065535]

向作者/读者索取更多资源

Hepatitis C virus (HCV) infection is frequently associated with the development of hepatocellular carcinoma (HCC), which is one of the male-dominant diseases. Androgen signaling in liver may be related to carcinogenesis. In this study, we investigated whether HCV proteins cross talk with the androgen receptor (AR) signaling pathway for promotion of carcinogenesis. We have demonstrated that HCV core protein alone or in context with other HCV proteins enhances AR-mediated transcriptional activity and further augments in the presence of androgen. Subsequent study suggested that HCV core protein activates STAT3, which in turn enhances AR-mediated transcription. This activity was blocked by a pharmacological inhibitor of the Jak/Stat signaling pathway, AG490. Vascular endothelial growth factor (VEGF) is a target gene of AR in liver and plays an important role in angiogenesis. Therefore, we examined whether HCV infection modulates VEGF expression in hepatocytes. Our results demonstrated that HCV enhances VEGF expression and facilitates tube formation in human coronary microvascular endothelial cells in the presence of AR. Together, our results suggest that HCV core protein acts as a positive regulator in AR signaling, providing further insight into oncogenic potential in the development of HCC in HCV-infected individuals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-5/Smad pathway suppression in hepatic stellate cells

Terunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, Tatsuya Kaneko, Junjie Ao, Na Qiang, Yaojia Ma, Jiaqi Zhang, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Motoyasu Kan, Miyuki Nakagawa, Kisako Fujiwara, Naoto Fujita, Takafumi Sakuma, Hiroaki Kanzaki, Keisuke Koroki, Yuko Kusakabe, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Ryo Nakagawa, Sadahisa Ogasawara, Shingo Nakamoto, Ryosuke Muroyama, Jun Kato, Tatsuo Kanda, Hitoshi Maruyama, Naoya Mimura, Takuya Honda, Toshihiko Murayama, Hiroyuki Nakamura, Naoya Kato

Summary: This study demonstrates that miglustat can suppress liver fibrosis by inhibiting the TGF-5/Smad pathway, reducing the expression of extracellular matrix components such as collagen. The research also shows that miglustat can both prevent the occurrence of liver fibrosis and reverse established fibrosis.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Thirty-two years' experience of treating fulminant hepatitis in a Japanese single center

Keiichi Fujiwara, Shin Yasui, Takayuki Kondo, Masato Nakamura, Makoto Arai, Tatsuo Kanda, Osamu Yokosuka, Masayuki Ohtsuka, Ryuzo Abe, Naoya Kato

Summary: The prognosis of patients with fulminant hepatitis and late-onset hepatic failure in Japan has not improved over the past 32 years, despite advancements in clinical management and liver transplantation. The increasing proportion of patients with poor prognosis and difficult-to-treat etiologies, as well as the aging population, may contribute to this lack of improvement.

HEPATOLOGY RESEARCH (2023)

Article Virology

Drug Screening for Hepatitis A Virus (HAV): Nicotinamide Inhibits c-Jun Expression and HAV Replication

Reina Sasaki-Tanaka, Ryota Masuzaki, Hiroaki Okamoto, Toshikatsu Shibata, Mitsuhiko Moriyama, Hirofumi Kogure, Tatsuo Kanda

Summary: This study identified nicotinamide as a potential therapeutic drug for HAV infection by inhibiting HAV replication through suppressing AP-1 activity and HAV IRES-mediated translation.

JOURNAL OF VIROLOGY (2023)

Article Surgery

Tumor stiffness measurement using magnetic resonance elastography can predict recurrence and survival after curative resection of hepatocellular carcinoma

Hayato Abe, Kazu Shibutani, Shintaro Yamazaki, Tatsuo Kanda, Mitsuhiko Moriyama, Masahiro Okada, Masahiko Sugitani, Shingo Tsuji, Tadatoshi Takayama, Yukiyasu Okamura

Summary: This study aimed to investigate the predictive value of preoperative tumor stiffness measured by magnetic resonance elastography on overall survival and recurrence-free survival in patients with hepatocellular carcinoma. The results showed that higher tumor stiffness was associated with increased risk of recurrence and death.

SURGERY (2023)

Article Oncology

Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors

Keita Ogawa, Tetsuhiro Chiba, Masato Nakamura, Jun Arai, Jiaqi Zhang, Yaojia Ma, Na Qiang, Junjie Ao, Sae Yumita, Takamasa Ishino, Motoyasu Kan, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Hiroaki Kanzaki, Keisuke Koroki, Yuko Kusakabe, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Ryo Nakagawa, Sadahisa Ogasawara, Ryosuke Muroyama, Shingo Nakamoto, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Shoji Matsumoto, Takayoshi Arai, Shinichiro Motohashi, Naoya Kato

Summary: In this study, the inhibition of ADAM9 was found to prevent the release of MICA and activate the immune function of NK cells. Through the screening of a chemical library, a compound called CCL347 with five benzene rings was identified, which significantly reduced sMICA levels in HCC cell lines and enhanced NK cell cytotoxicity, indicating its potential as a novel therapeutic drug for HCC.

ANTICANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Masitinib Inhibits Hepatitis A Virus Replication

Reina Sasaki-Tanaka, Toshikatsu Shibata, Mitsuhiko Moriyama, Hirofumi Kogure, Asuka Hirai-Yuki, Hiroaki Okamoto, Tatsuo Kanda

Summary: In this study, HuhT7-HAV/Luc cells were established as a suitable model for anti-HAV drug screening. Masitinib, a tyrosine kinase inhibitor, was found to reduce HAV replication and internal ribosomal entry-site (IRES) activity. It may be a potential treatment for severe HAV infection.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Molecular Mechanisms, Diagnosis and Treatments in Digestive Malignancy

Tatsuo Kanda, Ryota Masuzaki, Reina Sasaki-Tanaka, Hirofumi Kogure, Mitsuhiko Moriyama

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Editorial Material Biochemistry & Molecular Biology

Molecular Mechanism of Chronic Viral and Non-Viral Liver Diseases

Tatsuo Kanda

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis

Shini Kanezawa, Mitsuhiko Moriyama, Tatsuo Kanda, Akiko Fukushima, Ryota Masuzaki, Reina Sasaki-Tanaka, Akiko Tsunemi, Takahiro Ueno, Noboru Fukuda, Hirofumi Kogure

Summary: Metabolic-dysfunction-associated fatty-liver disease (MAFLD) is the leading cause of liver disease worldwide. Nonalcoholic steatohepatitis (NASH) patients have a higher prevalence of small-intestinal bacterial overgrowth (SIBO). In this study, we investigated the differences in gut microbiota between stroke-prone spontaneously hypertensive-5 rats (SHRSP5) fed a normal diet (ND) or a high-fat- and high-cholesterol-containing diet (HFCD). We found an association between MAFLD and gut microbiota alteration, suggesting that targeting gut microbiota may be a potential therapeutic approach for MAFLD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Gastroenterology & Hepatology

Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan

Tatsuo Kanda, Reina Sasaki-Tanaka, Koji Ishii, Ryosuke Suzuki, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, Ryuzo Abe, Keiichi Fujiwara, Osamu Yokosuka, Tian-Cheng Li, Satoshi Kunita, Hiroshi Yotsuyanagi, Hiroaki Okamoto

Summary: The Japan Agency for Medical Research and Development (AMED) Hepatitis A and E viruses (HAV and HEV) Study Group has reviewed the recent advances in HAV research and clinical practice for HAV infection in Japan and authored comprehensive guidelines. The article covers virological findings, clinical presentation, pathogenicity, diagnostic approaches, complications, risk factors, preventive measures, and treatment modalities for hepatitis A.

HEPATOLOGY RESEARCH (2023)

Article Medicine, General & Internal

Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection

Tatsuo Kanda, Naoki Matsumoto, Tomotaka Ishii, Shuhei Arima, Shinji Shibuya, Masayuki Honda, Reina Sasaki-Tanaka, Ryota Masuzaki, Shini Kanezawa, Masahiro Ogawa, Shintaro Yamazaki, Osamu Aramaki, Hirofumi Kogure, Yukiyasu Okamura

Summary: Through living-donor liver transplantation (LDLT) from a HLA-matched sibling donor, the use of immunosuppressants can potentially be stopped. The prognosis of liver transplantation may be affected by acute and chronic rejection reactions mediated by anti-HLA antibodies and T cells, as well as the underlying liver disease of the recipient. This case report highlights the importance of initiating direct-acting antiviral (DAA) therapy immediately after LDLT for hepatitis C virus (HCV) infection, in order to improve the prognosis of the recipients.

REPORTS (2022)

Article Medicine, Research & Experimental

COVID-19 After Treatment With Direct-acting Antivirals for HCV Infection and Decompensated Cirrhosis: A Case Report

Chikako Ikegami, Tatsuo Kanda, Tomotaka Ishii, Masayuki Honda, Yoichiro Yamana, Reina Sasaki Tanaka, Mariko Kumagawa, Shini Kanezawa, Taku Mizutani, Hiroaki Yamagami, Naoki Matsumoto, Ryota Masuzaki, Kentaro Hayashi, Kazushige Nirei, Tadateru Takayama, Mitsuhiko Moriyama

Summary: This case report describes a patient who developed recurrent COVID-19 pneumonia immediately after receiving combination treatment with DAAs for HCV infection. The patient was diagnosed with COVID-19 pneumonia 12 days after the end of treatment and experienced a second episode of recurrent COVID-19 pneumonia after discharge. However, the patient recovered from severe COVID-19 and achieved sustained virological response, with improvement in liver function.

IN VIVO (2022)

Article Oncology

Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience

Keita Ogawa, Hiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, Na Qiang, Yaojia Ma, Jiaqi Zhang, Sae Yumita, Takamasa Ishino, Hidemi Unozawa, Motoyasu Kan, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Naoto Fujita, Takafumi Sakuma, Keisuke Koroki, Yuko Kusakabe, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Sadahisa Ogasawara, Eiichiro Suzuki, Shingo Nakamoto, Ryosuke Muroyama, Tatsuo Kanda, Hitoshi Maruyama, Naoya Mimura, Jun Kato, Shinichiro Motohashi, Naoya Kato

Summary: The treatment effect of ATZ/BV in patients with HCC with CTNNB1 mutation is comparable to those without CTNNB1 mutation.

JOURNAL OF CANCER (2022)

Article Medicine, General & Internal

A Case of Recent Liver Injury Induced by Benzbromarone

Tomotaka Ishii, Keijiro Hoshino, Masayuki Honda, Yoichiro Yamana, Reina Sasaki-Tanaka, Mariko Kumagawa, Shini Kanezawa, Taku Mizutani, Naoki Matsumoto, Ryota Masuzaki, Kazushige Nirei, Hiroaki Yamagami, Mitsuhiko Moriyama, Tatsuo Kanda

Summary: This article describes a case of liver injury induced by benzbromarone in a male patient, emphasizing the importance of regular monitoring of liver function tests in patients taking benzbromarone.

REPORTS (2022)

Article Medicine, General & Internal

Left Gastric Vein Width Is an Important Risk Factor for Exacerbation of Esophageal Varices Post Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices in Cirrhotic Patients

Taku Mizutani, Kazushige Nirei, Tatsuo Kanda, Masayuki Honda, Tomotaka Ishii, Shuhei Arima, Yoichiro Yamana, Naoki Matsumoto, Shunichi Matsuoka, Mitsuhiko Moriyama

Summary: This study found that LGV width is a major risk factor for the deterioration of esophageal varices following BRTO in cirrhotic patients with gastric varices. More than half of the patients had LGV as the main inflow tract, and they experienced more frequent exacerbations of esophageal varices following BRTO compared to patients with different inflow tract sources.

MEDICINA-LITHUANIA (2022)

暂无数据